What's in Jun-Won Chung's pipeline?

Jun-Won Chung has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Jun-Won Chung's portfolio?

Top competitors by shared drug class: AVM Biotechnology Inc, Bayer, GBG Forschungs GmbH, HK inno.N Corporation, IBSA Institut Biochimique SA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jun-won-chung.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Jun-Won Chung — Portfolio Competitive Intelligence Brief

Jun-Won Chung pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
sequential versus triple	sequential versus triple	marketed	Proton pump inhibitor		Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AVM Biotechnology Inc · 1 shared drug class
Bayer · 1 shared drug class
GBG Forschungs GmbH · 1 shared drug class
HK inno.N Corporation · 1 shared drug class
IBSA Institut Biochimique SA · 1 shared drug class
Jason Lang, M.D., M.P.H. · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Samsung Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jun-Won Chung:

Cite this brief

Drug Landscape (2026). Jun-Won Chung — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jun-won-chung. Accessed 2026-05-13.